Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes
Luke A. Ephraums,
Edward R. Mignone,
Kylie Lange,
Ashlee Routley,
Judith Morton,
Emily Hopkins,
Sally Chapman,
Lucia Gagliardi,
Michael Horowitz,
Mahesh M. Umapathysivam Diabetes, Obesity and Metabolism
· Wiley
· 2026-11-04
· DOI: 10.1111/dom.71312
Аннотация
Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11986-11989, December 2026.
Luke A. Ephraums, Edward R. Mignone, Kylie Lange, Ashlee Routley, Judith Morton, Emily Hopkins et al. Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes. // Diabetes, Obesity and Metabolism. – 2026. – DOI: 10.1111/dom.71312. – URL: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71312?af=R
Luke A. Ephraums, Edward R. Mignone, Kylie Lange, Ashlee Routley, Judith Morton, Emily Hopkins, Sally Chapman, Lucia Gagliardi, Michael Horowitz, & Mahesh M. Umapathysivam (2026). Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71312
Luke A. Ephraums, et al. “Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes.” Diabetes, Obesity and Metabolism, 2026. doi:10.1111/dom.71312.
@article{Ephraums2026,
title = {Glucagon‐Like Peptide‐1 Receptor Agonist Use Is Associated With Improved Lung Function in Cystic Fibrosis‐Related Diabetes},
author = {Ephraums, Luke A. and Mignone, Edward R. and Lange, Kylie and Routley, Ashlee and Morton, Judith and Hopkins, Emily and Chapman, Sally and Gagliardi, Lucia and Horowitz, Michael and Umapathysivam, Mahesh M.},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71312},
url = {https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71312?af=R}
}